The Relationship of HER2 Copy Number Evaluated by Brightfield Dual In Situ Hybridisation DNA Assay and Pathologic Response to Neoadjuvant Treatment in HER2 Positive Breast Cancer

被引：0
|
作者：
Neville, G. [1 ]
Feeley, L. [1 ]
Bennett, M. W. [1 ]
O'Reilly, S. [1 ]
Corrigan, M. [1 ]
O'Connell, F. [1 ]
Browne, T. J. [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
来源：
JOURNAL OF PATHOLOGY | 2017年 / 243卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [21] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
    Zhao, Jing
    Krishnamurti, Uma
    Zhang, Chao
    Meisel, Jane
    Wei, Zhimin
    Suo, Aili
    Aneja, Ritu
    Li, Zaibo
    Li, Xiaoxian
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
  • [22] Assessment of HER2 status in breast cancer by fluorescence in situ hybridisation
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 235 - 236
  • [23] Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer?
    Silvia Antolín
    Lucía García-Caballero
    Cristina Reboredo
    Aurea Molina
    Joaquín Mosquera
    Ángel Vázquez-Boquete
    Rosalía Gallego
    Mari Paz Santiago
    Ángel Concha
    Eva Pérez
    Lourdes Calvo
    Tomás García-Caballero
    Virchows Archiv, 2021, 479 : 859 - 859
  • [24] In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
    Lien, Huang-Chun
    Lo, Chiao
    Lee, Yi-Hsuang
    Lin, Po-Hang
    Wang, Ming-Yang
    Kuo, Wen-Hung
    Tsai, Li-Wei
    Lu, Yen-Shen
    Hu, Hsiang-Wei
    Li, Yu-Chia
    Huang, Chiun-Sheng
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [25] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients?
    Altundag, Kadri
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 328 - 328
  • [26] Predictive Biomarker of Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [27] Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade
    Yoon, Ga Young
    Chae, Eun Young
    Cha, Joo Hee
    Shin, Hee Jung
    Choi, Woo Jung
    Kim, Hak Hee
    Kim, Jeong Eun
    Kim, Sung-Bae
    CLINICAL BREAST CANCER, 2020, 20 (01) : 25 - 32
  • [28] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Zheng-Jun Yang
    Fei Xin
    Zu-Jin Chen
    Yue Yu
    Xin Wang
    Xu-Chen Cao
    BMC Cancer, 24
  • [30] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
12345